Shamsi Suhaili, Tran Huong, Tan Renee Seok Jin, Tan Zee Jian, Lim Lee Yong
Laboratory for Drug Delivery, Centre for Optimization of Medicines, Pharmacy, School of Medicine and Pharmacology, University of Western Australia, Crawley, Australia (S.S., H.T., R.S.J.T., Z.J.T., L.Y.L.); Department of Biochemistry, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, Serdang, Malaysia (S.S.).
Laboratory for Drug Delivery, Centre for Optimization of Medicines, Pharmacy, School of Medicine and Pharmacology, University of Western Australia, Crawley, Australia (S.S., H.T., R.S.J.T., Z.J.T., L.Y.L.); Department of Biochemistry, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, Serdang, Malaysia (S.S.)
Drug Metab Dispos. 2017 Jan;45(1):49-55. doi: 10.1124/dmd.116.073213. Epub 2016 Nov 7.
Inhibition of cytochrome P450 (P450) enzymes (CYP) has been shown to lower the metabolism of drugs that are P450 substrates and to consequently alter their pharmacokinetic profiles. Curcumin (CUR), piperine (PIP), and capsaicin (CAP) are spice components (SC) that inhibit the activities of a range of P450 enzymes, but the selection of which SC to be prioritized for further development as an adjuvant will depend on the ranking order of the inhibitory potential of the SCs on specific P450 isozymes. We used common human recombinant enzyme platforms to provide a comparative evaluation of the inhibitory activities of CUR, PIP, and CAP on the principal drug-metabolizing P450 enzymes. SC-mediated inhibition of CYP3A4 was found to rank in the order of CAP (IC 1.84 ± 0.71 µM) ∼ PIP (2.12 ± 0.45 µM) > CUR (11.93 ± 3.49 µM), while CYP2C9 inhibition was in the order of CAP (11.95 ± 4.24 µM) ∼ CUR (14.58 ± 4.57 µM) > PIP (89.62 ± 9.17 µM). CAP and PIP were significantly more potent inhibitors of CYP1A2 (IC 2.14 ± 0.22 µM and 14.19 ± 4.15 µM, respectively) than CUR (IC > 100 µM), while all three SCs exhibited weak activity toward CYP2D6 (IC 95.42 ± 12.09 µM for CUR, 99.99 ± 5.88 µM for CAP, and 110.40 ± 3.23 µM for PIP). Of the three SCs, CAP thus has the strongest potential for further development into an inhibitor of multiple CYPs for use in the clinic. Data from this study are also useful for managing potential drug-SC interactions.
细胞色素P450(P450)酶(CYP)的抑制作用已被证明会降低作为P450底物的药物的代谢,从而改变其药代动力学特征。姜黄素(CUR)、胡椒碱(PIP)和辣椒素(CAP)是能够抑制一系列P450酶活性的香料成分(SC),但选择哪种SC作为佐剂进行进一步开发将取决于SC对特定P450同工酶的抑制潜力的排名顺序。我们使用常见的人类重组酶平台对CUR、PIP和CAP对主要药物代谢P450酶的抑制活性进行了比较评估。发现SC介导的CYP3A4抑制作用的排名顺序为CAP(IC 1.84±0.71µM)~PIP(2.12±0.45µM)>CUR(11.93±3.49µM),而CYP2C9抑制作用的顺序为CAP(11.95±4.24µM)~CUR(14.58±4.57µM)>PIP(89.62±9.17µM)。CAP和PIP作为CYP1A2的抑制剂(IC分别为2.14±0.22µM和14.19±4.15µM)比CUR(IC>100µM)的活性显著更强,而所有三种SC对CYP2D6均表现出较弱的活性(CUR的IC为95.42±12.09µM,CAP的IC为99.99±5.88µM,PIP的IC为110.40±3.23µM)。因此,在这三种SC中,CAP具有最强的进一步开发成用于临床的多种CYPs抑制剂的潜力。本研究的数据对于管理潜在的药物 - SC相互作用也很有用。